Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products worldwide. It operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. The company also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited is based in Salisbury South, Australia.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 8 8209 2666
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees780
Next Earnings DateN/A
OptionableNot Optionable
HedgePath Pharmaceuticals (OTCMKTS:MAYNF) Frequently Asked Questions
What is HedgePath Pharmaceuticals' stock symbol?
HedgePath Pharmaceuticals trades on the OTCMKTS under the ticker symbol "MAYNF."
What is the consensus analysts' recommendation for HedgePath Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HedgePath Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for HedgePath Pharmaceuticals.
Has HedgePath Pharmaceuticals been receiving favorable news coverage?
Headlines about MAYNF stock have been trending positive on Thursday, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. HedgePath Pharmaceuticals earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term. View News Stories for HedgePath Pharmaceuticals.
Who are some of HedgePath Pharmaceuticals' key competitors?
Who are HedgePath Pharmaceuticals' key executives?
HedgePath Pharmaceuticals' management team includes the folowing people:
- Mr. Scott Anthony Richards, MD, CEO & Exec. Director (Age 55)
- Mr. Nick Freeman BCom, CA, Group CFO & Company Sec.
- Mr. Stefan J. Cross, Pres of International Operations (Age 46)
- Dr. Ilana Stancovski, Chief Scientific Officer & Head of European Market Devel.
- Ms. Lisa Pendlebury, VP of Investor Relations & Communications
How do I buy shares of HedgePath Pharmaceuticals?
Shares of MAYNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is HedgePath Pharmaceuticals' stock price today?
One share of MAYNF stock can currently be purchased for approximately $0.3194.
What is HedgePath Pharmaceuticals' official website?
How can I contact HedgePath Pharmaceuticals?
The company can be reached via phone at 61 8 8209 2666.
MarketBeat Community Rating for HedgePath Pharmaceuticals (OTCMKTS MAYNF)
MarketBeat's community ratings are surveys of what our community members think about HedgePath Pharmaceuticals and other stocks. Vote "Outperform" if you believe MAYNF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MAYNF will underperform the S&P 500 over the long term. You may vote once every thirty days.
